Tianzuo Zhan

Dr. Tianzuo Zhan

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2016 in Oncogene
Verified
Journal Article
Open access
TZTianzuo Zhan
Tianzuo Zhan
NRN Rindtorff
N Rindtorff
MBMichael Boutros
Michael Boutros
Wnt signaling is one of the key cascades regulating development and stemness, and has also been tightly associated with cancer. The role of Wnt signaling in carcinogenesis has most prominently been described for colorectal cancer, but aberrant Wnt signaling is observed in many more cancer entities. Here, we review current insights into novel components of Wnt pathways and describe their impact on cancer development. Furthermore, we highlight expanding functions of Wnt signaling for both solid and liquid tumors. We also describe current findings how Wnt signaling affects maintenance of cancer stem cells, metastasis and immune control. Finally, we provide an overview of current strategies to antagonize Wnt signaling in cancer and challenges that are associated with such approaches.

1 April 2019 in Seminars in Cancer Biology
Verified
Journal Article
Open access
TZTianzuo Zhan
Tianzuo Zhan
NRNiklas Rindtorff
Niklas Rindtorff
JBJohannes Betge
Johannes Betge
MEMatthias P. Ebert
Matthias P. Ebert
MBMichael Boutros
Michael Boutros
CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of genes. As such, CRISPR/Cas9 promises to accelerate cancer research by providing an efficient technology to dissect mechanisms of tumorigenesis, identify targets for drug development, and possibly arm cells for cell-based therapies. Here, we review current applications of the CRISPR/Cas9 technology for cancer research and therapy. We describe novel Cas9 variants and how they are used in functional genomics to discover novel cancer-specific vulnerabilities. Furthermore, we highlight the impact of CRISPR/Cas9 in generating organoid and mouse models of cancer. Finally, we provide an overview of the first clinical trials that apply CRISPR/Cas9 as a therapeutic approach against cancer.

1 February 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SLSylvie Lorenzen
Sylvie Lorenzen
TGThorsten Oliver Götze
Thorsten Oliver Götze
PTPeter Thuss-Patience
Peter Thuss-Patience
Matthias BieblMatthias Biebl
Matthias Biebl
NHNils Homann
Nils Homann
FGfor the AIO and SAKK Study Working Groups
for the AIO and SAKK Study Working Groups
PURPOSE: This trial evaluates the addition of the PD-L1 antibody atezolizumab (ATZ) to standard-of-care fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) as a perioperative treatment for patients with resectable esophagogastric adenocarcinoma (EGA). METHODS: DANTE started as multicenter, randomized phase II trial, which was subsequently converted to a phase III trial. Here, we present the results of the phase II proportion, focusing on surgical pathology and safety outcomes on an exploratory basis. Patients with resectable EGA (≥cT2 or cN+) were assigned to either four preoperative and postoperative cycles of FLOT combined with ATZ, followed by eight cycles of ATZ maintenance (arm A) or FLOT alone (arm B). RESULTS: Two hundred ninety-five patients were randomly assigned (A, 146; B, 149) with balanced baseline characteristics between arms. Twenty-three patients (8%) had tumors with microsatellite instability (MSI), and 58% patients had tumors with a PD-L1 combined positive score (CPS) of ≥1. Surgical morbidity (A, 45%; B, 42%) and 60-day mortality (A, 3%; B, 2%) were comparable between arms. Downstaging favored arm A versus arm B (ypT0, 23% v 15% [one-sided P = .044]; ypT0-T2, 61% v 48% [one-sided P = .015]; ypN0, 68% v 54% [one-sided P = .012]). Histopathologic complete regression rates (pathologic complete response or TRG1a) were higher after FLOT plus ATZ (A, 24%; B, 15%; one-sided P = .032), and the difference was more pronounced in the PD-L1 CPS ≥10 (A, 33%; B, 12%) and MSI (A, 63%; B, 27%) subpopulations. Complete margin-free (R0) resection rates were relatively high in both arms (A, 96%; B, 95%). The incidence and severity of adverse events were similar in both groups. CONCLUSION: Within the limitations of the exploratory nature of the data, the addition of ATZ to perioperative FLOT is safe and improved postoperative stage and histopathologic regression.

1 May 2020 in Cell Stem Cell
Verified
Journal Article
Closed access
BMBirgitta E. Michels
Birgitta E. Michels
MMMohammed H. Mosa
Mohammed H. Mosa
BSBarbara I. Streibl
Barbara I. Streibl
TZTianzuo Zhan
Tianzuo Zhan
CMConstantin Menche
Constantin Menche
HFHenner F. Farin
Henner F. Farin

16 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TZTianzuo Zhan
Tianzuo Zhan
GAGiulia Ambrosi
Giulia Ambrosi
AWAnna Maxi Wandmacher
Anna Maxi Wandmacher
BRBenedikt Rauscher
Benedikt Rauscher
JBJohannes Betge
Johannes Betge
MBMichael Boutros
Michael Boutros
In colorectal cancer (CRC), aberrant Wnt signalling is essential for tumorigenesis and maintenance of cancer stem cells. However, how other oncogenic pathways converge on Wnt signalling to modulate stem cell homeostasis in CRC currently remains poorly understood. Using large-scale compound screens in CRC, we identify MEK1/2 inhibitors as potent activators of Wnt/β-catenin signalling. Targeting MEK increases Wnt activity in different CRC cell lines and murine intestine in vivo. Truncating mutations of APC generated by CRISPR/Cas9 strongly synergize with MEK inhibitors in enhancing Wnt responses in isogenic CRC models. Mechanistically, we demonstrate that MEK inhibition induces a rapid downregulation of AXIN1. Using patient-derived CRC organoids, we show that MEK inhibition leads to increased Wnt activity, elevated LGR5 levels and enrichment of gene signatures associated with stemness and cancer relapse. Our study demonstrates that clinically used MEK inhibitors inadvertently induce stem cell plasticity, revealing an unknown side effect of RAS pathway inhibition.

15 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
YQYuquan Qian
Yuquan Qian
Jimmy Daza BarraganJimmy Daza Barragan
Jimmy Daza Barragan
TITimo Itzel
Timo Itzel
JBJohannes Betge
Johannes Betge
TZTianzuo Zhan
Tianzuo Zhan
ATAndreas Teufel
Andreas Teufel
Current staging systems of cancer are mainly based on the anatomical extent of disease. They need refinement by biological parameters to improve stratification of patients for tumor therapy or surveillance strategies. Thanks to developments in genomic, transcriptomic, and big-data technologies, we are now able to explore molecular characteristics of tumors in detail and determine their clinical relevance. This has led to numerous prognostic and predictive gene expression signatures that have the potential to establish a classification of tumor subgroups by biological determinants. However, only a few gene signatures have reached the stage of clinical implementation so far. In this review article, we summarize the current status, and present and future challenges of prognostic gene signatures in three relevant cancer entities: breast cancer, colorectal cancer, and hepatocellular carcinoma.